Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1

Paone, Gregorino; Angelis, G. De; Munno, R.; Pallotta, G; Bigioni, D.; Saltini, Cesare; Bisetti, A; Ameglio, F.

doi:10.1183/09031936.95.08071136

Cited by 41 publications

(24 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present study ited (Stieber et al, 1993;Ebert et al, 1995;Paone et al, suggests that the determination of CYFRA 21-1 may provide Wieskopf et al., 1995), it is worthwhile investigating additional, independent, prognostic information in squaer pretreatment CYFRA 21-1 concentrations are mous-cell lung cancer patients. related to the likelihood of relapse in lung cancer patients who undergo curative resection.…”

Section: Discussionsupporting

confidence: 52%

Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer

Nikliński

Furman²,

Burzykowski³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary The CYFRA 21-1 assay is a test that has been developed recently for detection of a cytokeratin 19 fragment in serum. A diagnostic role for CYFRA 21-1 has already been proposed. The question of whether this marker is prognostically significant is important in clarifying the role of CYFRA 21-1 in clinical practice. The aim of this study was to evaluate the prognostic significance of elevated preoperative CYFRA 21-1 levels in patients with resected primary squamous-cell lung cancer (SqCC). Serum levels of CYFRA 21-1 were measured using an immunoradiometric assay (CIS bio) in 91 patients with operable SqCC. Survival and disease-free survival curves related to initial levels of this marker were estimated using the Kaplan-Meier method. In the univariate analysis the log-rank test and the log-rank test for trend were used. In the multivariate analysis the stratified log-rank test and the proportional hazard model were used. Elevated preoperative CYFRA 21-1 levels were identified in 55% of patients with SqCC. The number of patients with elevated levels of this marker increased with TNM stage (P=0.0001). In univariate analysis elevated levels of CYFRA 21-1 were significantly associated with poor overall survival (P<0.00005) and with disease-free survival (P<0.00005). In multivariate analysis elevated levels of this marker were also found to be associated with poor overall and disease-free survival (P=0.01 and P=0.003 respectively). In conclusion, CYFRA 21-1 may be an independent prognostic parameter of survival and tumour relapse in SqCC and may be useful in identifying resected SqCC patients at high risk of treatment failure.

show abstract

Section: Discussionsupporting

confidence: 52%

Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer

Nikliński

Furman²,

Burzykowski³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…This approach permitted generating a score able to correctly classify 95.9% of patients with an error rate of 8.3% in SCLC and 2.7% in NSCLC subjects. The formula to calculate this score was the following (Paone et al, 1995): The encouraging results obtained in the previous investigation led to the present study with the aim of: (1) verifying whether the above score showed the same discriminating power in a larger group of patients; and (2) analysing its reliability in different subgroups of lung cancer patients. antigen, produced by Byk Sangtec, Cormano, Italy; normal values less than 95 U ml-'); (3) CYFRA-21 .1 (a cytokeratin antigen, by CIS Diagnostici, Vercelli, Italy; normal values less than 3.3 ng ml-'); and (4) NSE (neuron-specific enolase, by CIS Diagnostici; normal values less than 12.5 ng ml-').…”

mentioning

confidence: 99%

Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors

Paone

Angelis²,

Portalone³

et al. 1997

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Summary By means of a mathematical score previoulsy generated by discriminant analysis on 90 lung cancer patients, a new and larger group of 261 subjects [209 with non-small-cell lung cancer (NSCLC) and 52 with small-cell lung cancer (SCLC)] was analysed to confirm the ability of the method to distinguish between these two types of cancers. The score, which included the serum neuron-specific enolase (NSE) and CYFRA-21.1 levels, permitted correct classification of 93% of the patients. When the misclassifications were analysed in detail, the most frequent errors were associated with limited disease SCLC with low NSE levels and with advanced NSCLC with high NSE levels. This demonstrates the importance of the marker in correctly categorizing patients.

show abstract

“…Similar studies have shown that increasing the number of samplings (repeated sampling in several sessions) significantly increases the sensitivity of mRNA biomarkers [29] [30]. This indicates that the odds of detecting markers are lower in a single sampling.…”

Section: Discussionmentioning

confidence: 53%

“…A number of nonsmall cell lung cancer patients who are recognized in primary stages of the disease and undergo surgery die due to tumor recurrence, which shows presence of undetectable metastasis at the time of surgery. These laboratory findings show that the currently used staging system does not have sufficient sensitivity for compartmentalization of cancer patients [30] [31].…”

Section: Discussionmentioning

confidence: 97%

Two Molecular Markers of Early Non-Small Cell Lung Carcinoma Based on Gene Expression in Peripheral Blood

Bahrami¹,

Jamaati²,

Nia³

et al. 2017

OJCD

View full text Add to dashboard Cite

Background: Lung cancer is among the most common cancers. Search is ongoing to find biomarkers to improve the diagnosis lung cancer techniques in early stages. In this study we evaluate the sensitivity and specificity of the MUC1 and CEA gene expressions in the peripheral blood of non-small cell lung cancer (NSCLC). Material and Methods: This study was done in Masih Daneshvari Hospital, Tehran, Iran and was case/control study that conducted on 30 NSCLC patients and 30 healthy controls. Peripheral blood was collected and total RNA was extracted then cDNA was synthesized. Sample was separately assessed by real time PCR. Results: The expression of CEA gen was positive in 24 patients indicating 80% sensitivity for this marker. The expression of CEA gen was positive in 9 controls out of 30 each. A statistically significant difference was detected between patients and healthy controls with regard to CEA mRNA expression (P < 0.001). The MUC1 gen expressed in 20 out of 30 patients, while it expressed in 3 controls. The difference in MUC1 mRNA expression was statistically significant between NSCLC patients and How to cite this paper:

show abstract

Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1

Cited by 41 publications

References 20 publications

Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer

Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer

Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors

Two Molecular Markers of Early Non-Small Cell Lung Carcinoma Based on Gene Expression in Peripheral Blood

Contact Info

Product

Resources

About